Comparison of (A) progression-free survival (PFS) and (B) overall survival (OS) of patients with advanced-stage follicular lymphoma who received either six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or six cycles of CHOP-RIT (cyclophosphamide, doxorubicin, vincristine, and prednisone followed by consolidation with iodine-133–tositumomab radioimmunotherapy).